Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2007.088302v1, 2007; 10.1373/clinchem.2007.088302
This Article
Right arrow Full Text (PDF)
Right arrow 088302.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2007.088302v1
53/11/1886    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vassalle, C.
Right arrow Articles by Emdin, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vassalle, C.
Right arrow Articles by Emdin, M.

Received on March 2, 2007
Accepted on August 29, 2007

Molecular Diagnostics and Genetics

Influence of ScaI and Natriuretic Peptide (NP) Clearance Receptor Polymorphisms of the NP System on NP Concentration in Chronic Heart Failure

Cristina Vassalle 1*, Maria Grazia Andreassi 1, Concetta Prontera 1, Marianna Fontana 1, Luc Zyw 1, Claudio Passino 2, Michele Emdin 1

1 Institute of Clinical Physiology, Consiglio Nazionale delle Ricerche, Pisa, Italy
2 Institute of Clinical Physiology, Consiglio Nazionale delle Ricerche, Pisa, Italy, and Scuola Superiore Sant'Anna, Pisa, Italy

* To whom correspondence should be addressed. E-mail: cristina.vassalle{at}ifc.cnr.it.

Background: Genetic variants related to the natriuretic peptide (NP) system [ScaI mutated allele (A1) of the atrial NP (ANP) gene and the C variant of the natriuretic peptide clearance receptor (NPRC) gene] have been identified as independent risk factors for cardiovascular morbidity and mortality. Despite the importance of NPs in heart failure (HF), however, the role of these polymorphisms in HF has not been evaluated.

Methods: We screened 124 HF patients [mean (SD), age 66 (12) years, 100 men, ejection fraction 32% (10%), New York Heart Association (NYHA) class I–II 65, III–IV 59] for NP concentrations [ANP, brain NP (BNP) and amino-terminal pro-BNP (NT-proBNP)] and for the ScaI and NPRC variants.

Results:ScaI polymorphism had no effect on NP concentration in the NYHA I–II subgroup. Conversely, in severe HF, A1 carriers had higher ANP (P ≤0.05), BNP (P <0.01), and NT-proBNP (P <0.01) than A2A2 patients. After multivariate adjustment, A1 presence remained an independent predictor for increased NP. Regarding NPRC polymorphism, higher ANP (P <0.05) and BNP (P <0.05) were observed in CC than A allele carriers, in mild HF. After multivariate adjustment, however, this association did not remain significant. In severe HF, the NPRC polymorphism had no effect on NP.

Conclusions: The ScaI polymorphism of the ANP gene might represent an important additive genetic factor influencing neurohormonal activation and disease progression in severe HF. The NPRC polymorphism is not an independent determinant of NP concentration in HF.




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
C. Vassalle and M. G. Andreassi
Genetic Polymorphisms of the Natriuretic Peptide System in the Pathogenesis of Cardiovascular Disease: What Lies on the Horizon?
Clin. Chem., May 1, 2009; 55(5): 878 - 887.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
P. Leszek and J. Korewicki
Independent effects of both right and left ventricular function on plasma brain natriuretic peptide levels
Eur J Heart Fail, March 1, 2008; 10(3): 328 - 328.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Association for Clinical Chemistry.